OOIR: Observatory of International Research

Papers

(The TQCC of Best Practice & Research Clinical Endocrinology & Metabolism is 12. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-02-01 to 2025-02-01.)

Article	Citations
Growth hormone replacement in adults with cured acromegaly: Efficacy and safety	79
Editorial Board	74
Recent progress in molecular classification of phaeochromocytoma and paraganglioma	71
Recent advances in algorithms predicting hemodynamic instability undergoing surgery for phaeochromocytoma and paraganglioma	70
Editorial Board	54
Publisher's Note	54
Editorial Board	50
Hormone therapy regimens for managing the menopause and premature ovarian insufficiency	42
Genetics of cryptorchidism and testicular regression	40
Newly detected diabetes during the COVID-19 pandemic: What have we learnt?	37
Genetics of reproductive endocrinology	35
Genotype-phenotype correlations in Graves’ disease	35
Editorial Board	34
Surgical outcomes in patients with acromegaly: Microscopic vs. endoscopic transsphenoidal surgery	32
Treatment of acromegaly with the nonpeptide, highly selective somatostatin receptor type 2 agonist paltusotine	30
Editorial Board	29
Editorial Board	29
Appropriate use of morphological imaging for assessing treatment response and disease progression of neuroendocrine tumors	29
Established and novel circulating neuroendocrine tumor biomarkers for diagnostic, predictive and prognostic use	28
Second line treatment of acromegaly: Pasireotide or Pegvisomant?	27
The novel concept of “Onco-Immuno-Endocrinology” led to the discovery of new clinical entity “paraneoplastic autoimmune hypophysitis”	27
Editorial Board	25
Next-generation therapeutic bacteria for treatment of obesity, diabetes, and other endocrine diseases	25
The pathophysiology of hypophosphatemia	24
Myeloma and marrow adiposity: Unanswered questions and future directions	24

Tyrosine Kinase Inhibitors and Immunotherapy Updates in Neuroendocrine Neoplasms	23
Differentiated thyroid carcinoma: An update	22
Clinical imaging of marrow adiposity	22
Menopausal hormone therapy for the management of osteoporosis	22
Nonalcoholic fatty liver disease and adult growth hormone deficiency: An under-recognized association?	22
Burosumab: Current status and future prospects	21
Post cancer care in women with an increased risk of malignancy or previous malignancy: The use of hormone replacement therapy and alternative treatments	20
Developments in interventional management of hepatic metastases from neuroendocrine tumours	20
Perinatal exposure to endocrine disrupting chemicals and neurodevelopment: How articles of daily use influence the development of our children	19
Ageing male (part I): Pathophysiology and diagnosis of functional hypogonadism	19
Genetics of congenital central hypogonadism	19
Endocrine disrupting chemicals and bone	19
COVID-19 vaccination and thyroiditis	19
Common symptoms associated with usage and cessation of anabolic androgenic steroids in men	19
Premature ovarian insufficiency, early menopause, and induced menopause	19
Genetics of pubertal timing	18
Meta-analysis of mortality in adults with growth hormone deficiency: Does growth hormone replacement therapy really improve mortality rates?	18
Genetics of anti-Müllerian hormone and its signaling pathway	17
Editorial Board	17
Progress in surgical approaches and outcomes of patients with pheochromocytoma and paraganglioma	16
Associations of prenatal exposure to phthalates and one phthalate substitute with anthropometric measures in early life: Results from the German LIFE Child cohort study	16
SDH-related head and neck paragangliomas: Unraveling PET radiomics beyond 18F-FDG	16
The role of androgens in transgender medicine	16
Polygenic risk scores for dyslipidemia and atherosclerotic cardiovascular disease: Progress toward clinical implementation	15
Pituitary and SARS CoV-2: An unremitting conundrum	15
Editorial Board	15
Editorial Board	15
Effective strategies for adequate control of hormonal secretion in functioning neuroendocrine neoplasms	15
Editorial Board	15
The gut microbiota as a versatile immunomodulator in obesity and associated metabolic disorders	15
Immune checkpoint inhibitor-related thyroid dysfunction	14
Role of unilateral adrenalectomy in bilateral adrenal hyperplasias with Cushing’s syndrome	14
Androgens part 2: Emerging areas	14
Impact of long-acting growth hormone replacement therapy in adult growth hormone deficiency: Comparison between adolescent, adult, and elderly patients	13
Editorial Board	13
Regulation of bone mass: A splendid Orchestra	13
Inherited fibroblast growth factor 23 excess	13
Mild traumatic brain injury as a cause of adult growth hormone deficiency: Diagnosis and treatment	13
Current views on the role of HIF-2α in the pathogenesis and syndromic presentation of pheochromocytoma and paraganglioma	12
Exercise and physical activity in individuals at risk of fracture	12
“Micromegaly”: Acromegaly with apparently normal GH, an entity on its own?	12
Androgens in male contraception	12
Chemokines in thyroid autoimmunity	12
Best practice & research clinical endocrinology & metabolism focusing on the menopause – Diagnostic and therapeutic strategies	12
Vitamin D deficiency or resistance and hypophosphatemia	12
Cognitive health after menopause: Does menopausal hormone therapy affect it?	12
Editorial Board	12
Pre-clinical phaeochromocytoma and paraganglioma models: Cell lines, animal models, and a human primary culture model	12
Coronavirus disease 2019 and vitamin D	12
The gut microbiome, a hidden endocrine organ with widespread metabolic implications?	12